The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs. It is often called “immortal cancer” due to the difficulties in disease treatment. As the cornerstone of immune regulation, the programmed cell death protein 1 (PD-1) has been extensively studied in the con...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bing, Chen, Can, Liu, Xia, Zhou, Shuang, Xu, Ting, Wu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030866/
https://www.ncbi.nlm.nih.gov/pubmed/36969198
http://dx.doi.org/10.3389/fimmu.2023.1111005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030866/
https://www.ncbi.nlm.nih.gov/pubmed/36969198
http://dx.doi.org/10.3389/fimmu.2023.1111005

Ejemplares similares